Ternary Health
Featured condition · Madelung's Disease

Madelung's Disease

Benign symmetric lipomatosis is rare enough that many patients have never met a physician who has seen more than a handful of cases. Our flagship condition.

Overview

What we mean when we say Madelung's Disease.

Madelung's Disease — also known as benign symmetric lipomatosis or Launois-Bensaude syndrome — is a rare disorder characterized by the symmetric accumulation of non-encapsulated adipose tissue, most commonly in the neck, shoulders, and upper back.

Despite being classified as benign, it can produce substantial functional and cosmetic impact, and is associated in the literature with metabolic, hepatic, and neurologic findings that often go unexplored in routine care.

Because the condition is uncommon, most clinicians encounter it rarely, and case-specific expertise is difficult to assemble across a single medical team.

Why it’s hard to navigate

The pattern we see in Madelung's Disease cases.

Signals we look for

The Ternary Signal Library for Madelung's Disease.

Our Signal Library codifies the specific patterns that matter in Madelung's Disease — labs, genetic variants, imaging findings, symptom clusters, and comorbidity combinations. Your case is mapped against these signals in Stage 4 of the workflow; each activated signal is weighted and prioritized for your presentation.

Laboratory markers
  • Triglycerides, LDL-C, HDL, ApoB — dyslipidemia patterns
  • ALT, AST, GGT, ALP — hepatic involvement
  • Ferritin, transferrin saturation, iron — iron overload axis
  • HbA1c, fasting insulin — metabolic syndrome indicators
  • Testosterone (total, free), SHBG — common Madelung-adjacent findings
  • Vitamin D, B12, B6 (PLP) — correctable deficiencies
Genetic variants
  • HFE — C282Y and H63D — iron overload risk
  • APOE — metabolic context
  • ADH1B / ALDH2 — alcohol-metabolism variants
  • Mitochondrial variants (limited in consumer genotyping)
  • Lipid-metabolism genes relevant to subtype
Imaging & anatomy
  • Contrast-enhanced MRI of the neck — depth of infiltration
  • Distribution pattern — Type I / II / III classification
  • Deep vs. superficial cervical extension
  • Airway compromise assessment
  • Sleep study findings if OSA is suspected
Comorbidity patterns
  • Chronic alcohol exposure timeline
  • Obstructive sleep apnea and neck-mass airway effects
  • Fatty liver / hepatic fibrosis status
  • Peripheral neuropathy, autonomic dysfunction
  • Prior surgical history and recurrence pattern
How we approach it

The Ternary Health approach to Madelung's Disease.

01

Review the full history — imaging, distribution, prior surgeries, associated findings — and classify the presentation against published subtypes where the data supports it.

02

Integrate labs, hepatic workup, metabolic markers, and any autonomic or neurologic findings into a single view, rather than treating them as separate complaints.

03

If genomic data is available, look for variants associated with mitochondrial function and lipid metabolism that have been linked to Madelung-type presentations in the literature.

04

Map the surgical and medical options — evidence base, typical outcomes, trade-offs between aggressive and conservative approaches — so you can make informed decisions with your surgical team.

The nine-stage workflow, applied

How a Madelung's Disease case moves through our workflow.

Our nine-stage workflow is the same for every engagement. What changes per condition is the content at each stage — the records we pull, the signals we apply, the specialists we map, the pathways we evaluate. Below, how your case specifically would move through each stage.

Stage 01 · Days 0–2
Qualification
Fit screen confirms diagnosed or strongly suspected Madelung's Disease, access to records, and pre- or post-surgical status. Alcohol history and surgical decision timing matter for case prioritization.
Stage 02 · Days 3–7
Intake & data aggregation
Records pull emphasizes neck imaging, hepatic workup, iron studies, and lipid panels. Alcohol history is built as a timeline rather than a single intake question. Optional 23andMe / whole-genome upload.
Stage 03 · Days 7–9
Case structuring
Case schema populated. MSL subtype (Type I / II / III) evaluated. Genetic variants — HFE, APOE, alcohol-metabolism — flagged if genomic data is available. Timeline reconstructed chronologically.
Stage 04 · Days 9–12
Signal analysis
The Ternary Signal Library for Madelung's Disease is applied. Typical case activates 10–15 signals across six domains: alcohol, iron, metabolic, surgical-anatomy, mitochondrial, nutritional. Each signal weighted for your specific presentation.
Stage 05 · Days 10–14
Evidence retrieval
Literature scan emphasizes the small set of centers with published Madelung's Disease series: Gdansk (Lacka et al.), Qingdao (Luan et al.), Bologna (Pinto, Piccin), Padova (Enzi, Busetto), and the Cleveland Clinic deoxycholic acid work. Condition-specific Evidence Matrix refreshed.
Stage 06 · Days 14–17
Pathway mapping
Pathway map built across surgical (head-and-neck vs. plastic/reconstructive), medical (fenofibrate, salbutamol, deoxycholic acid), lifestyle (alcohol cessation, Mediterranean pattern), and monitoring domains. Specialists mapped from our Specialist Graph.
Stage 07 · Days 17–20
Synthesis & plan construction
Interventions scored on the Ternary Method. Dependencies encoded as a directed graph — typically alcohol cessation unblocks iron reassessment, which informs phlebotomy decision, which informs surgery-readiness evaluation.
Stage 08 · Days 20–25
Delivery & calibration
Findings call with attention to surgical decision timing, airway management planning for anesthesia, and pre-op lymphatic therapy training. Your priorities and constraints update the plan before finalization.
Stage 09 · Days 25–55
Execution support
30 days of asynchronous follow-up through the typical Madelung's Disease consultation sequence — PCP, hepatology, sleep medicine, and two surgical opinions. Outcomes captured into the Ledger.
Deliverables

What you receive.

  • A written case synthesis covering distribution, subtype, and associated findings
  • Integration of imaging, labs, and metabolic workup into a single view
  • Optional genome-informed analysis highlighting relevant variants
  • A surgical / non-surgical decision framework grounded in the literature
  • Specialist identification for consultations you may want to consider
  • A written action plan and follow-up support as you implement it
Common questions — Madelung's Disease

What prospective Madelung's Disease clients ask most.

Is Madelung's Disease curable?
No current medicine reliably dissolves established Madelung's Disease masses. What is changeable is the trajectory — rate of progression, recurrence risk after surgery, and the metabolic and airway comorbidities that often matter more than the masses themselves.
Do I need a formal diagnosis before applying?
A diagnosis is preferred but not required. If you have imaging or clinical notes that suggest Madelung's Disease or multiple symmetric lipomatosis, we can help you evaluate the differential. We do not make diagnoses, but we can frame the picture your physicians are evaluating.
Can you help me choose between liposuction and open excision?
Yes. Surgical decision support is a core part of our Madelung's Disease work — reviewing imaging for depth of infiltration, comparing center-by-center recurrence data, and preparing you for parallel consultations with head-and-neck and plastic-reconstructive surgeons.
What if I'm outside the US?
Our specialist map includes published Madelung's Disease centers in Europe and Asia (Gdańsk, Bologna, Padova, Qingdao, Melbourne). We work with clients globally and include international consultation pathways where travel is a reasonable option.
How does alcohol history factor into the plan?
Heavily. Chronic alcohol exposure is implicated in the majority of published Madelung's Disease cases, and alcohol cessation is consistently the single highest-leverage non-surgical intervention. We build an honest, structured cessation pathway into every plan where alcohol use is part of the picture.

Ready for a case review?

Applications are reviewed within three business days.